
Introduction: Fear of progression, anxiety and depression are highly interconnected in breast cancer patients and survivors, and they shape adaptation to the disease. Materials and Methods: This observational, cross-sectional, multicentre, non-interventional study was conducted in two hospitals in Romania during one month (July 2026). A total of 120 patients with breast cancer were assessed with three questionnaires: the Hospital Anxiety and Depression Scale (HADS), the Illness Cognition Questionnaire (ICQ) and the Short Fear of Progression Questionnaire (FoP-12). Results: Anxiety reached at least the borderline band in 58 patients (48.3%) and depression in 59 patients (49.2%). Fear of progression was dysfunctional in 46 patients (38.3%). High acceptance (64, 53.3%) and high perceived benefits (61, 50.8%) each described about half the sample, whereas high helplessness was uncommon (10, 8.3%). Discussion: Anxiety and depression were strongly related (ρ = .77, 95% CI [.67, .84], p < .001). Helplessness, anxiety, depression and fear of progression were all significantly and positively intercorrelated, with coefficients from .27 to .77, all q < .01. Conclusions: Anxiety, depression and fear of progression were common and closely interrelated, whereas differences between patient subgroups were few and modest once multiple testing was taken into account. These findings are exploratory and support routine psychological screening of breast cancer patients, but they do not identify established risk factors.
The right to oncological forgetting is a protective measure aimed at ensuring non-discrimination for individuals who have recovered from cancer and at safeguarding their right not to disclose past health information, particularly in contractual, insurance, and employment contexts. However, its practical application raises several legal issues concerning access to medical records and the role of caregivers, who are often involved in managing the patient’s care. Access to medical records is also crucial for continuity of care and the exercise of rights, raising ethical and legal questions related to confidentiality, representation, and informed consent—from diagnosis through post-treatment. The interaction of these three domains requires a balance between privacy protection, administrative simplification, and the centrality of the cancer survivor. This article/project reflects on the evolution of legislation and its practical implications for patients, families, and healthcare professionals, highlighting the need for shared comparative pathways and clear guidelines.
Plant-derived extracts, such as those obtained from Acmella oleracea (L.) R.K. Jansen (AO), have drawn increasing interest due to possible neuroprotective properties. Several reports of neuroprotective potential were attributed to the main bioactive component of AO extract, spilanthol. Due to its capacity of spilanthol to cross the blood-brain barrier and to modulate serotonergic and GABAergic systems, AO extract may represent a promising experimental candidate for investigating effects on autism spectrum disorder (ASD) relevant behavioural symptoms, such as anxiety and aggression. The most common drug to model core symptoms of autism spectrum disorder (ASD) in zebrafish is the antiepileptic valproic acid (VPA). The current study aimed to evaluate the behavioural effects of AO extract in zebrafish, as compared to or in combination with VPA, to assess their effects on anxiety-like and aggressive behaviour, as assessed by the novel tank test (NTT) and the mirror-biting test (MBT). Our findings suggest that VPA-treated zebrafish show an increased frequency of aggressive and anxiety-like behaviours, as compared to controls. Similar anxiety-like, but not aggressive, behavioural changes were seen in AO-treated zebrafish. These effects may be connected with the modulation of GABAergic neurotransmission. Moreover, we observed that acute AO extract treatment was not able to modulate aggressive behaviour in VPA-treated or in healthy zebrafish.
Dynamic surgical scheduling must accommodate uncertain procedure durations, emergency arrivals, resource outages, and competing access and workload objectives. This paper presents NeuroCare Grid, a multi-agent scheduling architecture coordinated through an interpretable, multi-channel stigmergic field, and evaluates NeuroCare-H, its deterministic heuristic implementation. In a disclosed 30-day discrete-event simulation involving 500 synthetic admissions and an emergency share of 15.2%, NeuroCare-H achieved a scheduling rate of 92.47% ± 1.92%, an emergency waiting time of 0.01 ± 0.01 days, and operating-room utilization of 98.18% ± 1.20%. The corresponding FCFS results were 87.68% ± 1.02%, 0.40 ± 0.11 days, and 94.65% ± 1.96%, respectively. All three comparisons were based on 30 paired seeds and remained significant after Holm correction, with p < 0.00001. The scheduling advantage over FCFS persisted when the workload was increased to two and three times the baseline level. However, urgency-based scheduling produced a less equal distribution of waiting times, with a Gini coefficient of 0.63 for NeuroCare-H compared with 0.36 for FCFS. Removing the field slightly increased the scheduling rate from 92.47% to 92.81%, but worsened the Gini coefficient from 0.63 to 0.70. Replacing the multi-channel field with a pooled scalar produced no detectable difference. In a separate bootstrap experiment based on 37 surgical admissions from the open MIMIC-III Demo, the emergency share increased to 78.4%, and the scheduling-rate difference between NeuroCare-H and FCFS was no longer statistically significant (p = 0.13). These results establish a reproducible heuristic benchmark within the stated simulator and support the need for external operational validation before clinical use.
Long-term occupational exposure to low-frequency whole-body vibration (WBV) is a recognised risk factor for musculoskeletal disorders. Given that mechanical forces are transmitted systemically, similar effects may plausibly extend to the central nervous system (CNS), although this remains insufficiently investigated. Emerging evidence suggests that WBV exposure may act as a source of repetitive subclinical brain microtrauma, described as minimal (mi-TBI). These low-intensity insults do not produce immediate clinical symptoms or detectable abnormalities on conventional neuroimaging (CT or MRI), but may accumulate and contribute to delayed neuronal dysfunction and long-term neurological consequences. Oxidative stress appears to be central to this process. Increased reactive oxygen species production, combined with impaired antioxidant defenses, may induce lipid peroxidation, mitochondrial dysfunction, neuroinflammation, and blood–brain barrier disruption. Similar mechanisms are established in vibration-exposed peripheral tissues, supporting the plausibility of analogous CNS effects. This review examines the hypothesis that chronic WBV exposure contributes to CNS oxidative imbalance and early neurodegenerative processes. Particular emphasis is placed on oxidative stress biomarkers—including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT)—as potential tools for detecting subclinical brain alterations. Additionally, neurofunctional evaluation and emerging technologies such as virtual reality–based tools, are highlighted for detecting subtle cognitive changes. By integrating mechanistic, molecular, and occupational perspectives, we propose a conceptual framework in which WBV is considered a potential source of subclinical mild traumatic brain injury (m-TBI). However, this hypothesis remains supported primarily by indirect evidence and requires validation in human occupational studies.